ABSTRACT
This chapter provides a short overview of the pathophysiology and the treatment options in the case of bioresorbable scaffolds (BRSs) failure with a focus on the most frequently used bioresorbable vascular scaffolds (BVSs) and some remarks for the other faster resorbing scaffolds. With the use of BRSs in more complex lesions, also the incidence of BRSs failure, including both scaffold restenosis and thrombosis (ScT), has increased. In the case of a geographical miss with apparent edge restenosis, placement of an additional BRSs is possible although converting to a drug eluting stents (DESs) with a minimal risk of repeat in-stent restenosis (ISR) is more prudent. In severely calcified or tortuous lesions, successful delivery of BRSs can be difficult and the scaffold could be potentially dislodged in the same way as metallic stents. BRSs thrombosis after dual antiplatelet therapy (DAPT) interruption, whether acute, subacute, or late, can be managed with the use of thrombectomy, glycoprotein IIbIIIa inhibitor (GPI), and/or balloon angioplasty (POBA).
